Clinical outcomes amongst elderly patients with inflammatory bowel disease
© 2022 Royal Australasian College of Physicians..
BACKGROUNDS AND AIMS: Inflammatory bowel disease (IBD) affects a growing cohort of elderly patients. Our aim was to compare the quality of care received by elderly patients with IBD with a nonelderly adult IBD population using clinical markers including steroid-free clinical remission.
METHOD: Retrospective audit of all consecutive patients attending a specialist IBD centre over a 1-year period aged >60 (elderly cohort [EC]) and 50 consecutive patients aged 30-45 years (control cohort [CC]). A follow-up survey was completed assessing current symptoms and perceptions of care.
RESULTS: One hundred thirty-nine patients were evaluated (89 EC, 50 CC). Steroid-free clinical remission was observed less commonly in the EC (58, 64%) compared with the CC (40, 80%) (P < 0.05). Biologics such as infliximab (15% EC vs 36% CC; P < 0.01) and adalimumab (14% EC vs 30% CC; P = 0.02) were used less frequently in the EC, whilst vedolizumab (6% EC vs 6% CC; P = 1) and ustekinumab (3% EC vs 2% CC; P = 1) were used at a similar frequency. Patients in the EC were less likely to have specialist IBD nursing contact (P < 0.01), smoking screening (P < 0.011) or influenza vaccinations (P < 0.006). IBD nurse contact was associated with significantly greater provision of the preventative care measures.
CONCLUSION: Elderly patients with IBD were less likely to experience steroid-free clinical remission or be prescribed biologics. Elderly patients were less likely to receive education with respect to preventative medicine. The models of care for the elderly need re-evaluation and greater incorporation with the multidisciplinary IBD team.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Internal medicine journal - 53(2023), 10 vom: 01. Okt., Seite 1866-1874 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sivanathan, Vithoosharan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B72HH48FLU |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 20.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/imj.15928 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346291380 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346291380 | ||
| 003 | DE-627 | ||
| 005 | 20231226031056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/imj.15928 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346291380 | ||
| 035 | |a (NLM)36112394 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sivanathan, Vithoosharan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes amongst elderly patients with inflammatory bowel disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 20.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Royal Australasian College of Physicians. | ||
| 520 | |a BACKGROUNDS AND AIMS: Inflammatory bowel disease (IBD) affects a growing cohort of elderly patients. Our aim was to compare the quality of care received by elderly patients with IBD with a nonelderly adult IBD population using clinical markers including steroid-free clinical remission | ||
| 520 | |a METHOD: Retrospective audit of all consecutive patients attending a specialist IBD centre over a 1-year period aged >60 (elderly cohort [EC]) and 50 consecutive patients aged 30-45 years (control cohort [CC]). A follow-up survey was completed assessing current symptoms and perceptions of care | ||
| 520 | |a RESULTS: One hundred thirty-nine patients were evaluated (89 EC, 50 CC). Steroid-free clinical remission was observed less commonly in the EC (58, 64%) compared with the CC (40, 80%) (P < 0.05). Biologics such as infliximab (15% EC vs 36% CC; P < 0.01) and adalimumab (14% EC vs 30% CC; P = 0.02) were used less frequently in the EC, whilst vedolizumab (6% EC vs 6% CC; P = 1) and ustekinumab (3% EC vs 2% CC; P = 1) were used at a similar frequency. Patients in the EC were less likely to have specialist IBD nursing contact (P < 0.01), smoking screening (P < 0.011) or influenza vaccinations (P < 0.006). IBD nurse contact was associated with significantly greater provision of the preventative care measures | ||
| 520 | |a CONCLUSION: Elderly patients with IBD were less likely to experience steroid-free clinical remission or be prescribed biologics. Elderly patients were less likely to receive education with respect to preventative medicine. The models of care for the elderly need re-evaluation and greater incorporation with the multidisciplinary IBD team | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Crohn's | |
| 650 | 4 | |a elderly | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a quality of care | |
| 650 | 4 | |a ulcerative colitis | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Basnayake, Chamara |e verfasserin |4 aut | |
| 700 | 1 | |a Connell, William |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, John Nik |e verfasserin |4 aut | |
| 700 | 1 | |a Niewadomski, Ola |e verfasserin |4 aut | |
| 700 | 1 | |a Stanley, Annalise |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson-O'Brien, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Fry, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Samyue, Tamie |e verfasserin |4 aut | |
| 700 | 1 | |a Lust, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Flanagan, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Alexander J V |e verfasserin |4 aut | |
| 700 | 1 | |a Kamm, Michael A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine journal |d 2001 |g 53(2023), 10 vom: 01. Okt., Seite 1866-1874 |w (DE-627)NLM113582811 |x 1445-5994 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2023 |g number:10 |g day:01 |g month:10 |g pages:1866-1874 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/imj.15928 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2023 |e 10 |b 01 |c 10 |h 1866-1874 | ||